Lilly Provides Indian Generic Drug for Humanitarian Access to Baricitinib for COVID-19 While the Daily Case Count Appears to Decline Now

Lilly Provides Indian Generic Drug for Humanitarian Access to Baricitinib for COVID-19 While the Daily Case Count Appears to Decline Now

Eli Lilly expedited the availability of baricitinib in India for COVID-19 patients via the signing of a voluntary licensing agreement with Natco Pharma. Based on a royalty-free, non-exclusive voluntary license to Natco Pharma based in Hyderabad, the American pharmaceutical company will extensively collaborate to ensure the availability of the drug during the pandemic. Presenting that this deal will improve local treatment options, Lilly also announced six similar voluntary license agreements with other Indian pharmaceutical companies including Cipla, Lupin, Sun Pharmaceutical Industries, Dr. Reddy’s, MSN Laboratories, and Torrent Pharmaceuticals. Meanwhile, India’s daily SARS-COV-2 cases rate appears to be falling fast and several states such as the nation’s most populated, Uttar Pradesh, intensified a population-wide Ivermectin treatment program—and new cases in that state have dramatically declined.

What is Baricitinib?

Known under the brand name Olumiant, this drug is used for the treatment of rheumatoid arthritis in adults whose disease is not under control using rheumatoid arthritis medications known as tumor necrosis factor antagonists. Rather, this falls in a cla...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee